GeoVax Labs (NASDAQ:GOVX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of GeoVax Labs (NASDAQ:GOVX) from a sell rating to a hold rating in a report published on Saturday.

Other equities research analysts have also issued research reports about the stock. Alliance Global Partners decreased their price target on shares of GeoVax Labs from $15.00 to $8.50 and set a “buy” rating for the company in a research note on Tuesday, April 15th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price objective on shares of GeoVax Labs in a report on Monday, June 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a report on Wednesday, April 16th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, GeoVax Labs currently has an average rating of “Buy” and an average price target of $11.10.

GeoVax Labs Stock Down 7.3%

Shares of GOVX stock opened at $0.87 on Friday. The company has a 50 day moving average of $0.99 and a 200-day moving average of $1.51. GeoVax Labs has a 12-month low of $0.73 and a 12-month high of $11.18. The firm has a market cap of $13.29 million, a P/E ratio of -0.24 and a beta of 3.45.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.14. GeoVax Labs had a negative net margin of 438.20% and a negative return on equity of 511.96%. The company had revenue of $1.64 million during the quarter, compared to analyst estimates of $0.75 million. As a group, equities analysts expect that GeoVax Labs will post -4.49 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GOVX. Jane Street Group LLC bought a new position in GeoVax Labs in the 1st quarter valued at $27,000. Northern Trust Corp bought a new position in GeoVax Labs in the 4th quarter valued at $29,000. Citadel Advisors LLC bought a new position in GeoVax Labs in the 4th quarter valued at $104,000. Geode Capital Management LLC boosted its holdings in GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares during the period. Finally, Armistice Capital LLC bought a new position in GeoVax Labs in the 1st quarter valued at $703,000. 6.09% of the stock is owned by institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.